More than 30,000 visitors from all parts of the globe gathered in Munich for this year’s ESC (European Society of Cardiology) Congress (Aug. 30 – Sept. 3), one of the most important cardiology congresses in the world. And of course, Bayer (a founding father of the conference and major sponsor) was more than represented. With a total of six satellite symposia, plus many other activities, as well, Bayer Schering Pharma's Business Unit General Medicine was able to spread the word regarding its longstanding experience and competence in Cardiovascular Risk Managememnt (CVRM) and the effectiveness of its products.
Delegates roaming the hall could stop at the 300 sqm booth space, where CVRM presented Adalat, Pritor/Kinzal, Aspirin Cardio and Glucobay under the strategic motto 'Connecting Cardiovascular Prevention Strategies.' Such tools as a CVRM screen animation, an eLearning game and a code breaker quiz illustrated perfectly the CVRM strategy, the coexisting and overlapping CV risk factors in many patients -- e.g., hypertension, diabetes and established CVD -- and how optimal treatment should offer benefits for comprehensive risk factor management, as the CVRM products do. Other brands represented at the booth included Ventavis and, since diagnostic imaging was the official topic at the Congress, there was also information on the Business Unit Diagnostic Imaging with Ultravist and Vasovist. The concept of 'connecting' was taken literally since the booth was connected to a 150 sqm Xarelto exhibit, which was similar in both style and concept and highlighted and rounded off the impressing presence of Bayer Schering Pharma at the ESC.
